A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer

Radiology and Oncology

Jingjing Kang^3¹  Meng Yuan^3²  Yu Men^2³  Li Ma^1⁴  Xin Sun^3⁵  Lingling Feng^1⁶ 

[1] Peking Union Medical College, 100021, Beijing, China^2;Peking Union Medical College, 100021, Beijing, China^3;Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 518116, Shenzhen, China^1;Department of Radiation Oncology, National Cancer Center/Cancer Hospital &Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences &Department of VIP Medical Services, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences &

关键词: non-small cell lung cancer;    dose escalation;    hyperfractionation;    hypofractionation;    adaptive radiotherapy;    proton radiotherapy;    carbon ion radiotherapy;   

DOI  :  10.2478/raon-2019-0006

学科分类：肿瘤学

来源: Onkoloski Institut Ljubljana / Institute of Oncology Ljubljana

【 摘 要 】

BackgroundThe mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the predominant failure patterns. Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival. However, the large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared with 60 Gy by simply increasing fraction numbers.

【 授权许可】

Unknown